A leading US biopharma company will run clinical trials in Ireland for a new drug it hopes will provide a breakthrough for an aggravating skin condition.
Fast-growing Regeneron, started in 1988, is still managed by its founders and has a broad range of targets, both with drugs already on the market and those coming through its pipeline.
Its flagship product is ophthamology drug Eylea, which treats wet age-related macular degeneration.
Fast-growing Regeneron, started in 1988, is still managed by its founders and has a broad range of targets, both with drugs already on the market and those coming through its pipeline.
Its flagship product is ophthamology drug Eylea, which treats wet age-related macular degeneration.
